The DPP7 Knockout NCI-H1299 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1299 human non-small cell lung carcinoma line. This heterogeneous pool carries targeted disruption of the DPP7 gene, which encodes lysosomal dipeptidyl peptidase 7, a serine protease that cleaves N-terminal dipeptides from oligopeptide substrates. The gene-edited population enables loss-of-function studies without clonal isolation, preserving the genetic diversity inherent to the parental line while abolishing DPP7 expression across the polyclonal culture.
The parental NCI-H1299 cell line was established from a lymph node metastasis of a lung adenocarcinoma and is widely employed as a model for metastatic non-small cell lung carcinoma. These epithelial cells are deficient in p53 and harbor wild-type KRAS and EGFR alleles, providing a defined genetic background that is permissive for studying tumor-suppressor-independent mechanisms of malignancy. The absence of common driver mutations allows researchers to investigate DPP7-associated phenotypes without confounding effects from hyperactive MAPK or PI3K signaling pathways.
DPP7 functions in the lysosomal lumen, where it removes N-terminal dipeptides from oligopeptides during terminal protein degradation, facilitating amino acid recycling. It may generate antigenic peptides for MHC class I presentation, influencing adaptive immune surveillance. DPP7 interacts with lysosomal membrane proteins including LAMPs and functionally associates with cathepsins. Its downstream substrates include chemokines and neuropeptides; upstream regulators are unknown. Key pathway components are DPP7, cathepsins, LAMPs, and MHC class I.
In the context of NCI-H1299 cells, DPP7 disruption is particularly relevant for investigating how lysosomal proteolysis modulates the biology of metastatic lung adenocarcinoma. Because these cells are p53-deficient, DPP7 loss may reveal compensatory proteolytic pathways or alterations in amino acid metabolism that support tumor cell survival under nutrient stress. The wild-type KRAS and EGFR status further emphasizes the unique role of DPP7 in pathways distinct from canonical oncogenic signaling. Additionally, the reported involvement of DPP7 in quiescent cell homeostasis suggests that this model can be used to explore mechanisms of tumor dormancy and metastatic latency.
This knockout population is ideally suited for a broad range of experimental applications, including the study of lysosomal proteolysis in cancer, antigen processing and presentation, and quiescent cell biology. Researchers can employ Western blotting, RT-qPCR, and DPP7 enzymatic activity assays to confirm gene disruption and assess residual protease function. Immunofluorescence for lysosomal markers such as LAMP1 and cathepsins, combined with proteomic profiling, enables detailed characterization of lysosomal composition. Functional analyses may include cell viability, apoptosis, and migration/invasion assays to evaluate the impact on metastatic behavior. For further details, please contact Ascent Research.
